Idorsia Pharmaceuticals at HCRTR1
As of the edition of 20 October 2026, Idorsia Pharmaceuticals is on route B at HCRTR1 (orexin/Hypocretin receptor type 1), position 16 of 2,016 on that route, with a score of 0.763.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.763
Biology proven in humans0.85
How much the company cares0.90
Room, and a reason to act now0.58
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Active at the target or its disease area recently+0.176
Few other companies active at the target+0.128
Trials at the target more often meet than miss their main endpoint+0.051
The company’s own follow-on drug-0.044
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 10 August 2026.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 7 April 2022.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 7 April 2022.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Daridorexant | Marketed | Phase 4 | 48 | Patent ends: 2 December 2034 |
| Almorexant | Went quiet | Phase 3 | 6 | none listed |
| ACT-462206 | Went quiet | Phase 1 | 1 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT06498128 | Daridorexant | Recruiting | 2024 to 2033 | 785 | No results posted | |
| NCT06393504 | Daridorexant | Active not recruiting | 2023 to 2028 | 2,095 | No results posted | |
| NCT05877222 | Daridorexant | Phase 1 | Completed | 2023 to 2023 | 38 | No results posted |
| NCT05597020 | Daridorexant | Phase 4 | Completed | 2023 to 2024 | 60 | Main endpoint met |
| NCT05632393 | Daridorexant | Phase 1 | Completed | 2023 to 2023 | 10 | No results posted |
| NCT05702177 | Daridorexant | Phase 1 | Completed | 2023 to 2023 | 36 | No results posted |
| NCT05423717 | Daridorexant | Phase 2 | Completed | 2022 to 2026 | 166 | No results posted |
| NCT05480475 | Daridorexant | Phase 1 | Completed | 2022 to 2022 | 24 | No results posted |
| NCT05480488 | Daridorexant | Phase 1 | Completed | 2022 to 2022 | 18 | No results posted |
| NCT05458193 | Daridorexant | Phase 1 | Completed | 2022 to 2023 | 20 | No results posted |
| NCT04390334 | Daridorexant | Phase 1 | Completed | 2020 to 2020 | 24 | No results posted |
| NCT04250506 | Daridorexant | Phase 1 | Completed | 2020 to 2020 | 36 | No results posted |